Cargando…

CYP2D6 Genotype Predicts Tamoxifen Discontinuation and Prognosis in Patients With Breast Cancer

PURPOSE: To examine the association between CYP2D6 genotype, discontinuation of tamoxifen therapy, and prognosis for breast cancer. PATIENTS AND METHODS: We conducted a prospective-retrospective study linking data from a clinical breast cancer register, the Swedish Prescribed Drug Register, and self...

Descripción completa

Detalles Bibliográficos
Autores principales:	He, Wei, Grassmann, Felix, Eriksson, Mikael, Eliasson, Erik, Margolin, Sara, Thorén, Linda, Hall, Per, Czene, Kamila
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Clinical Oncology 2020
Materias:	ORIGINAL REPORTS
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7030887/ https://www.ncbi.nlm.nih.gov/pubmed/31800347 http://dx.doi.org/10.1200/JCO.19.01535

Ejemplares similares

Impact of systemic adjuvant therapy and CYP2D6 activity on mammographic density in a cohort of tamoxifen-treated breast cancer patients
por: Thorén, Linda, et al.
Publicado: (2021)

Time to Mammographic Density Decrease After Exposure to Tamoxifen
por: Bäcklund, Magnus, et al.
Publicado: (2022)

Impairment of endoxifen formation in tamoxifen‐treated premenopausal breast cancer patients carrying reduced‐function CYP2D6 alleles
por: Thorén, Linda, et al.
Publicado: (2020)

Low-Dose Tamoxifen for Mammographic Density Reduction: A Randomized Controlled Trial
por: Eriksson, Mikael, et al.
Publicado: (2021)

Use of Low-Dose Tamoxifen to Increase Mammographic Screening Sensitivity in Premenopausal Women
por: Eriksson, Mikael, et al.
Publicado: (2021)

Association of CYP2D6 metabolizer status with mammographic density change in response to tamoxifen treatment
por: Li, Jingmei, et al.
Publicado: (2013)

Hyperthyroidism is associated with breast cancer risk and mammographic and genetic risk predictors
por: Yang, Haomin, et al.
Publicado: (2020)

Interval breast cancer is associated with other types of tumors
por: Grassmann, Felix, et al.
Publicado: (2019)

Mammographic features are associated with cardiometabolic disease risk and mortality
por: Grassmann, Felix, et al.
Publicado: (2021)

Adherence to endocrine therapy in early breast cancer in relation to Cytochrome P450 2D6 genotype: a comparison between pharmacy dispensation data and medical records
por: Thorén, Linda, et al.
Publicado: (2023)

CYP2D6 genotype and tamoxifen response
por: Rae, James M, et al.
Publicado: (2005)

Discontinuation of adjuvant hormone therapy among breast cancer patients not previously attending mammography screening
por: He, Wei, et al.
Publicado: (2019)

The Impact of CYP2D6 Genotyping on Tamoxifen Treatment
por: Ferraldeschi, Roberta, et al.
Publicado: (2010)

Is breast cancer prognosis inherited?
por: Hartman, Mikael, et al.
Publicado: (2007)

The association of single nucleotide polymorphisms (SNPs) with breast density and breast cancer survival: the Malmö Diet and Cancer Study
por: Sartor, Hanna, et al.
Publicado: (2020)

Prediction of breast cancer risk for sisters of women attending screening
por: Mao, Xinhe, et al.
Publicado: (2023)

Association between breast cancer risk and disease aggressiveness: Characterizing underlying gene expression patterns
por: Ugalde‐Morales, Emilio, et al.
Publicado: (2020)

Side effects of low-dose tamoxifen: results from a six-armed randomised controlled trial in healthy women
por: Hammarström, Mattias, et al.
Publicado: (2023)

Associations between childhood body size and seventeen adverse outcomes: analysis of 65,057 European women
por: Li, Jingmei, et al.
Publicado: (2017)

A comprehensive tool for measuring mammographic density changes over time
por: Eriksson, Mikael, et al.
Publicado: (2018)

Estimating Distributions of Breast Cancer Onset and Growth in a Swedish Mammography Screening Cohort
por: Strandberg, Rickard, et al.
Publicado: (2022)

A systems genomics approach to uncover the molecular properties of cancer genes
por: Grassmann, Felix, et al.
Publicado: (2020)

Detection of potential microcalcification clusters using multivendor for‐presentation digital mammograms for short‐term breast cancer risk estimation
por: Alsheh Ali, Maya, et al.
Publicado: (2019)

A Clinical Risk Model for Personalized Screening and Prevention of Breast Cancer
por: Eriksson, Mikael, et al.
Publicado: (2023)

Long-Term Performance of an Image-Based Short-Term Risk Model for Breast Cancer
por: Eriksson, Mikael, et al.
Publicado: (2023)

CYP2D6 Genotype and Adjuvant Tamoxifen: Meta-Analysis of Heterogeneous Study Populations
por: Province, M A, et al.
Publicado: (2014)

Determinants of Mammographic Density Change
por: Azam, Shadi, et al.
Publicado: (2019)

A clinical model for identifying the short-term risk of breast cancer
por: Eriksson, Mikael, et al.
Publicado: (2017)

Sense of coherence and risk of breast cancer
por: Hu, Kejia, et al.
Publicado: (2020)

Adjuvant Therapy and Mammographic Density Changes in Women With Breast Cancer
por: Eriksson, Louise, et al.
Publicado: (2019)

Chinese breast cancer patients with CYP2D6*10 mutant genotypes have a better prognosis with toremifene than with tamoxifen
por: Wang, Hongyue, et al.
Publicado: (2021)

Correction to: Deciphering the genetic and epidemiological landscape of mitochondrial DNA abundance
por: Hägg, Sara, et al.
Publicado: (2021)

Deciphering the genetic and epidemiological landscape of mitochondrial DNA abundance
por: Hägg, Sara, et al.
Publicado: (2020)

Is Genetic Background Important in Lung Cancer Survival?
por: Lindström, Linda S., et al.
Publicado: (2009)

Identification of two novel mammographic density loci at 6Q25.1
por: Brand, Judith S, et al.
Publicado: (2015)

Effect of CYP3A4*22, CYP3A5*3, and CYP3A combined genotypes on tamoxifen metabolism
por: Sanchez Spitman, A. B., et al.
Publicado: (2017)

CYP2D6 genotype affects outcome in postmenopausal breast cancer patients treated with tamoxifen monotherapy
por: Thompson, AM, et al.
Publicado: (2010)

CYP2D6 Genotype and Tamoxifen Response for Breast Cancer: A Systematic Review and Meta-Analysis
por: Lum, Danny W. K., et al.
Publicado: (2013)

National Prociency Testing Result of CYP2D6*10 Genotyping for Adjuvant Tamoxifen Therapy in China
por: Lin, Guigao, et al.
Publicado: (2016)

Improved Prediction of Endoxifen Metabolism by CYP2D6 Genotype in Breast Cancer Patients Treated with Tamoxifen
por: Schroth, Werner, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_bb79b4eadkjm42g5h6bl83jok2